492 related articles for article (PubMed ID: 28985766)
21. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
[TBL] [Abstract][Full Text] [Related]
23. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer.
Janatova M; Kleibl Z; Stribrna J; Panczak A; Vesela K; Zimovjanova M; Kleiblova P; Dundr P; Soukupova J; Pohlreich P
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2323-32. PubMed ID: 24136930
[TBL] [Abstract][Full Text] [Related]
24. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
Torres D; Rashid MU; Gil F; Umana A; Ramelli G; Robledo JF; Tawil M; Torregrosa L; Briceno I; Hamann U
Breast Cancer Res Treat; 2007 Jun; 103(2):225-32. PubMed ID: 17080309
[TBL] [Abstract][Full Text] [Related]
25. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
27. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications.
Kurian AW
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):72-8. PubMed ID: 19841585
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
Jackson SA; Davis AA; Li J; Yi N; McCormick SR; Grant C; Fallen T; Crawford B; Loranger K; Litton J; Arun B; Vande Wydeven K; Sidani A; Farmer K; Sanders M; Hoskins K; Nussbaum R; Esserman L; Garber JE; Kaklamani VG;
Cancer; 2014 May; 120(10):1557-64. PubMed ID: 24522996
[TBL] [Abstract][Full Text] [Related]
30. Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus.
Sokolenko AP; Bakaeva EK; Venina AR; Kuligina ES; Romanko AA; Aleksakhina SN; Belysheva YV; Belogubova EV; Stepanov IA; Zaitseva OA; Yatsuk OS; Togo AV; Khamgokov ZM; Kadyrova AO; Pirmagomedov AS; Bolieva MB; Epkhiev AA; Tsutsaev AK; Chakhieva MD; Khabrieva KM; Khabriev IM; Murachuev MA; Buttaeva BN; Baboshkina LS; Bayramkulova FI; Katchiev IR; Alieva LK; Raskin GA; Orlov SV; Khachmamuk ZK; Levonyan KR; Gichko DM; Kirtbaya DV; Degtyariov AM; Sultanova LV; Musayeva HS; Belyaev AM; Imyanitov EN
Breast Cancer Res Treat; 2024 Jan; 203(2):307-315. PubMed ID: 37851290
[TBL] [Abstract][Full Text] [Related]
31. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
[TBL] [Abstract][Full Text] [Related]
32. Recurrent large genomic rearrangements in BRCA1 and BRCA2 in an Irish case series.
McVeigh TP; Cody N; Carroll C; Duff M; Farrell M; Bradley L; Gallagher D; McDevitt T; Green AJ
Cancer Genet; 2017 Aug; 214-215():1-8. PubMed ID: 28595730
[TBL] [Abstract][Full Text] [Related]
33. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
34. BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries.
Cherbal F; Bakour R; Adane S; Boualga K
Breast Dis; 2012; 34(1):1-8. PubMed ID: 23697973
[TBL] [Abstract][Full Text] [Related]
35. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
Saxena S; Chakraborty A; Kaushal M; Kotwal S; Bhatanager D; Mohil RS; Chintamani C; Aggarwal AK; Sharma VK; Sharma PC; Lenoir G; Goldgar DE; Szabo CI
BMC Med Genet; 2006 Oct; 7():75. PubMed ID: 17018160
[TBL] [Abstract][Full Text] [Related]
36. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
[TBL] [Abstract][Full Text] [Related]
37. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
38. Identification of a novel in-frame deletion in BRCA2 and analysis of variants of BRCA1/2 in Italian patients affected with hereditary breast and ovarian cancer.
Vietri MT; Molinari AM; Laura De Paola M; Cantile F; Fasano M; Cioffi M
Clin Chem Lab Med; 2012 Dec; 50(12):2171-80. PubMed ID: 23096105
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
Riahi A; Chabouni-Bouhamed H; Kharrat M
Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
[TBL] [Abstract][Full Text] [Related]
40. Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients.
Manguoğlu E; Güran S; Yamaç D; Colak T; Simşek M; Baykara M; Akaydın M; Lüleci G
Cancer Genet Cytogenet; 2010 Dec; 203(2):230-7. PubMed ID: 21156238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
